|
ANZCTR. 2021.
This is an observational cohort study assessing the serological response to COVID-19 vaccination in kidney and kidney pancreas transplant recipients and patients treated with maintenance dialysis at Auckland City Hospital. Three analyses will be undertaken:
1. Vaccine immunogenicity based on humoral and cellular responses. Serological testing for the antibody to SARS-CoV-2 will be done prior to vaccination and again at 1 and 3 weeks and 6 months after the booster vaccination in dialysis and transplant recipients. Cellular responses will be assessed at 3 weeks after the booster vaccination.
2. Development of anti-HLA antibodies in dialysis patients on the kidney transplant waiting list in the first 12 months after vaccination.
3. Development of acute rejection episodes at 1, 4, 8 and 12 weeks after vaccination in recipients of kidney and kidney-pancreas transplants.
https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=367259&isReview=true
|
|
|
ClinicalTrials.gov. 2021.
The purpose of this study is to investigate the efficient vaccine type as a booster dose for Coronavirus Disease of 2019 (COVID-19) in solid organ transplant recipients.
https://clinicaltrials.gov/show/NCT05047640
|
|
|
ClinicalTrials.gov. 2018.
|
|
|
Clinicaltrials.gov. 2014.
|
|
|
Clinicaltrials.gov. 2014.
|
|
|
Clinicaltrials.gov. 2014.
|
|
|
Clinicaltrials.gov. 2014.
|
|
|
Clinicaltrials.gov. 2013.
|
|
|
Clinicaltrials.gov. 2013.
|
|
|
Clinicaltrials.gov. 2013.
|